Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 175

1.

Emtricitabine + tenofovir alafenamide for the treatment of HIV.

Corado KC, Daar ES.

Expert Opin Pharmacother. 2017 Feb 2. doi: 10.1080/14656566.2017.1288720. [Epub ahead of print]

PMID:
28151023
2.

HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.

Karris MY, Jain S, Day TR, Pérez-Santiago J, Goicoechea M, Dubé MP, Sun X, Spina C, Daar ES, Haubrich RH, Morris S; California Collaborative Treatment Group (CCTG) 589 Study Team..

HIV Clin Trials. 2017 Jan 30:1-8. doi: 10.1080/15284336.2017.1282578. [Epub ahead of print]

PMID:
28134057
3.

Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.

Verma A, Bradford Y, Verma SS, Pendergrass SA, Daar ES, Venuto C, Morse GD, Ritchie MD, Haas DW.

Pharmacogenet Genomics. 2017 Mar;27(3):101-111. doi: 10.1097/FPC.0000000000000263.

4.

Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial.

Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, Jain MK, Rodriguez AE, Armstrong WS, Lucas GM, Nijhawan AE, Drainoni ML, Herrera P, Vergara-Rodriguez P, Jacobson JM, Mugavero MJ, Sullivan M, Daar ES, McMahon DK, Ferris DC, Lindblad R, VanVeldhuisen P, Oden N, Castellón PC, Tross S, Haynes LF, Douaihy A, Sorensen JL, Metzger DS, Mandler RN, Colfax GN, del Rio C.

JAMA. 2016 Jul 12;316(2):156-70. doi: 10.1001/jama.2016.8914.

PMID:
27404184
5.

Condomless Sex With Virologically Suppressed HIV-Infected Individuals: How Safe Is It?

Daar ES, Corado K.

JAMA. 2016 Jul 12;316(2):149-51. doi: 10.1001/jama.2016.5636. No abstract available.

PMID:
27404181
6.

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD.

Clin Infect Dis. 2016 Jul 15;63(2):268-80. doi: 10.1093/cid/ciw236.

PMID:
27090986
7.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, Johnson M, Clumeck N, Osiyemi O, Ward D, Morales-Ramirez J, Yan M, Abram ME, Plummer A, Cheng AK, Rhee MS.

Lancet HIV. 2016 Apr;3(4):e158-65. doi: 10.1016/S2352-3018(16)00024-2.

PMID:
27036991
8.

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

Karris MY, Jain S, Bowman VQ, Rieg G, Goicoechea M, Dube MP, Kerkar S, Kemper C, Diamond C, Sun X, Daar ES, Haubrich RH, Morris S; California Collaborative Treatment Group (CCTG) 589 Study Team..

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e48-50. doi: 10.1097/QAI.0000000000000990. No abstract available.

PMID:
26977746
9.

Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART.

Dan JM, Massanella M, Smith DM, Spina CA, Schrier R, Daar ES, Dube MP, Morris SR, Gianella S.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):133-7. doi: 10.1097/QAI.0000000000000936.

10.

Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy.

Gianella S, Ginocchio CC, Daar ES, Dube MP, Morris SR.

BMC Infect Dis. 2016 Jan 25;16:24. doi: 10.1186/s12879-016-1356-y.

11.

Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection.

Vanpouille C, Introini A, Morris SR, Margolis L, Daar ES, Dube MP, Little SJ, Smith DM, Lisco A, Gianella S.

AIDS. 2016 Jan;30(2):193-201. doi: 10.1097/QAD.0000000000000964.

12.

Randomized Controlled Trial of an Internet Application to Reduce HIV Transmission Behavior Among HIV Infected Men Who have Sex with Men.

Milam J, Morris S, Jain S, Sun X, Dubé MP, Daar ES, Jimenez G, Haubrich R; CCTG 592 Team..

AIDS Behav. 2016 Jun;20(6):1173-81. doi: 10.1007/s10461-015-1215-7.

PMID:
26487300
13.

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy.

Massanella M, Gianella S, Schrier R, Dan JM, Pérez-Santiago J, Oliveira MF, Richman DD, Little SJ, Benson CA, Daar ES, Dube MP, Haubrich RH, Smith DM, Morris SR.

Sci Rep. 2015 Aug 24;5:13179. doi: 10.1038/srep13179.

14.

Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.

Wanga V, Venuto C, Morse GD, Acosta EP, Daar ES, Haas DW, Li C, Shepherd BE.

Pharmacogenet Genomics. 2015 Sep;25(9):450-61. doi: 10.1097/FPC.0000000000000156.

15.

Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men.

Gianella S, Smith DM, Daar ES, Dube MP, Lisco A, Vanpouille C, Margolis L, Haubrich RH, Morris SR.

PLoS One. 2015 Jun 10;10(6):e0130410. doi: 10.1371/journal.pone.0130410.

16.

Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.

Longenecker CT, Kitch D, Sax PE, Daar ES, Tierney C, Gupta SK, McComsey GA; AIDS Clinical Trials Group Study A5224s Team..

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):168-77. doi: 10.1097/QAI.0000000000000557.

17.

Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.

Moore CB, Verma A, Pendergrass S, Verma SS, Johnson DH, Daar ES, Gulick RM, Haubrich R, Robbins GK, Ritchie MD, Haas DW.

Open Forum Infect Dis. 2015 Jan 9;2(1):ofu113. doi: 10.1093/ofid/ofu113.

18.

A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.

Broglio KR, Daar ES, Quintana M, Yuan Y, Kalsekar A, Spellberg B, Lewis RJ, Akker Dv, Detry MA, Le T, Berry SM.

J Comp Eff Res. 2015 Mar;4(2):101-14. doi: 10.2217/cer.14.69. Review.

PMID:
25825840
19.

Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.

Gupta SK, Kitch D, Tierney C, Daar ES, Sax PE, Melbourne K, Ha B, McComsey GA; AIDS Clinical Trials Group Study A5224s Team..

Open Forum Infect Dis. 2014 Apr 16;1(1):ofu003. doi: 10.1093/ofid/ofu003.

20.

A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV.

Moore BA, Rosen MI, Wang Y, Shen J, Ablondi K, Sullivan A, Guerrero M, Siqueiros L, Daar ES, Liu H.

AIDS Behav. 2015 Jun;19 Suppl 2:156-62. doi: 10.1007/s10461-014-0990-x.

Items per page

Supplemental Content

Loading ...
Support Center